Adjuvant Sintilimab Plus Capecitabine in Nasopharyngeal Carcinoma
Status:
Not yet recruiting
Trial end date:
2026-02-15
Target enrollment:
Participant gender:
Summary
This randomized clinical trial determining whether Sintilimab plus Capecitabine versus
Capecitabine alone can improve the progression-free survival rate of NPC patients with
unfavorable response to induction chemotherapy. Patients whose plasma EBV DNA> 0 copy/mL or
SD/PD according to RECIST1.1 after two cycles induction chemotherapy will have concurrent
chemoradiotherapy. MRI, CT and EBV DNA will be assessed before the end of radiotherapy. After
concurrent chemoradiotherapy, eligible patients will be randomized to receive either adjuvant
Sintilimab plus Capecitabine or Capecitabine alone.